BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24163082)

  • 1. Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.
    Jiang G; Li RH; Sun C; Jia HY; Lei TC; Liu YQ
    Tumour Biol; 2014 Jan; 35(1):315-22. PubMed ID: 24163082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
    Teimouri F; Nikfar S; Abdollahi M
    Melanoma Res; 2013 Oct; 23(5):381-9. PubMed ID: 23880781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis.
    Jiang G; Li RH; Sun C; Liu YQ; Zheng JN
    PLoS One; 2014; 9(12):e111920. PubMed ID: 25502446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide for the treatment of metastatic melanoma: a systematic review.
    Quirt I; Verma S; Petrella T; Bak K; Charette M
    Oncologist; 2007 Sep; 12(9):1114-23. PubMed ID: 17914081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis.
    Sun H; Du S; Liao G; Xie X; Ren C; Yuan YW
    Medicine (Baltimore); 2015 May; 94(20):e827. PubMed ID: 25997057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
    Ashby LS; Smith KA; Stea B
    World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
    Brada M; Stenning S; Gabe R; Thompson LC; Levy D; Rampling R; Erridge S; Saran F; Gattamaneni R; Hopkins K; Beall S; Collins VP; Lee SM
    J Clin Oncol; 2010 Oct; 28(30):4601-8. PubMed ID: 20855843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
    Middleton MR; Friedlander P; Hamid O; Daud A; Plummer R; Falotico N; Chyla B; Jiang F; McKeegan E; Mostafa NM; Zhu M; Qian J; McKee M; Luo Y; Giranda VL; McArthur GA
    Ann Oncol; 2015 Oct; 26(10):2173-9. PubMed ID: 26202595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
    Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
    Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D
    Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole brain irradiation and temozolomide based chemotherapy in melanoma brain metastases.
    Conill C; Jorcano S; Domingo-Doménech J; Gallego R; Malvehy J; Puig S; Sánchez M; Vilella R; Castel T
    Clin Transl Oncol; 2006 Apr; 8(4):266-70. PubMed ID: 16648102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide for Treating Malignant Melanoma.
    Li RH; Hou XY; Yang CS; Liu WL; Tang JQ; Liu YQ; Jiang G
    J Coll Physicians Surg Pak; 2015 Sep; 25(9):680-8. PubMed ID: 26374366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant or adjuvant temozolomide with whole-brain irradiation for brain metastases: a meta-analysis.
    Liu R; Wang X; Ma B; Yang K; Zhang Q; Tian J
    Anticancer Drugs; 2010 Jan; 21(1):120-8. PubMed ID: 19881333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
    Kaufmann R; Spieth K; Leiter U; Mauch C; von den Driesch P; Vogt T; Linse R; Tilgen W; Schadendorf D; Becker JC; Sebastian G; Krengel S; Kretschmer L; Garbe C; Dummer R;
    J Clin Oncol; 2005 Dec; 23(35):9001-7. PubMed ID: 16260697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
    Bafaloukos D; Tsoutsos D; Kalofonos H; Chalkidou S; Panagiotou P; Linardou E; Briassoulis E; Efstathiou E; Polyzos A; Fountzilas G; Christodoulou C; Kouroussis C; Iconomou T; Gogas H
    Ann Oncol; 2005 Jun; 16(6):950-7. PubMed ID: 15829494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.
    de Gast GC; Batchelor D; Kersten MJ; Vyth-Dreese FA; Sein J; van de Kasteele WF; Nooijen WJ; Nieweg OE; de Waal MA; Boogerd W
    Br J Cancer; 2003 Jan; 88(2):175-80. PubMed ID: 12610499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
    Gogas H; Polyzos A; Stavrinidis I; Frangia K; Tsoutsos D; Panagiotou P; Markopoulos C; Papadopoulos O; Pectasides D; Mantzourani M; Middleton M; Vaiopoulos G; Fountzilas G
    Ann Oncol; 2006 Dec; 17(12):1835-41. PubMed ID: 16980601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.